Clinical management of patients with deep vein thrombosis (DVT) is centered around their risk of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome (PTS) [1]. In both conditions, inflammation is considered to play a major pathogenic role, including through its impact on hypercoagulability and residual venous obstruction (RVO) [1,2]. Therefore, it could be expected that patients with chronic inflammatory diseases (CID) have an increased risk of developing these long-term complications.
